This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Osborne, C. S.
Right arrow Articles by Ryder, N. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osborne, C. S.
Right arrow Articles by Ryder, N. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2009, p. 3777-3781, Vol. 53, No. 9
0066-4804/09/$08.00+0     doi:10.1128/AAC.00026-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

In Vivo Characterization of the Peptide Deformylase Inhibitor LBM415 in Murine Infection Models {triangledown}

Colin S. Osborne,* Georg Neckermann,{dagger} Evelin Fischer,{ddagger} Robert Pecanka, Donghui Yu, Kari Manni, Julie Goldovitz, Kerri Amaral, JoAnn Dzink-Fox, and Neil S. Ryder

Infectious Diseases, Novartis Institutes for BioMedical Research Inc., Cambridge, Massachusetts 02139

Received 7 January 2009/ Returned for modification 16 February 2009/ Accepted 19 June 2009

LBM415 is an antibacterial agent belonging to the peptide deformylase inhibitor class of compounds. It has previously been shown to demonstrate good activity in vitro against a range of pathogens. In this study, the in vivo efficacy of LBM415 was evaluated in various mouse infection models. We investigated activity against a systemic infection model caused by intraperitoneal inoculation of Staphylococcus aureus (methicillin [meticillin] susceptible [MSSA] and methicillin resistant [MRSA]) and Streptococcus pneumoniae (penicillin susceptible [PSSP] and multidrug resistant [MDRSP]), a thigh infection model caused by intramuscular injection of MRSA, and a lung infection produced by intranasal inoculation of PSSP. In the systemic MSSA and MRSA infections, LBM415 was equivalent to linezolid and vancomycin. In the systemic PSSP infection, LBM415 was equivalent to linezolid, whereas against systemic MDRSP infection, the LBM415 50% effective dose (ED50) was 4.8 mg/kg (dosed subcutaneously) and 36.6 mg/kg (dosed orally), compared to 13.2 mg/kg for telithromycin and >60 mg/kg for penicillin V and clarithromycin. In the MRSA thigh infection, LBM415 significantly reduced thigh bacterial levels compared to those of untreated mice, with levels similar to those after treatment with linezolid at the same dose levels. In the pneumonia model, the ED50 to reduce the bacterial lung burden by >4 log10 in 50% of treated animals was 23.3 mg/kg for LBM415, whereas moxifloxacin showed an ED50 of 14.3 mg/kg. In summary, LBM415 showed in vivo efficacy in sepsis and specific organ infection models irrespective of resistance to other antibiotics. Results suggest the potential of peptide deformylase inhibitors as a novel class of therapeutic agents against antibiotic-resistant pathogens.

* Corresponding author. Mailing address: Infectious Diseases, Room 8654, Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, MA 02139. Phone: (617) 871-3142. Fax: (617) 871-7058. E-mail: colin.osborne{at}novartis.com

{triangledown} Published ahead of print on 13 July 2009.

{dagger} Present address: AstraZeneca Pharmaceuticals, Waltham, MA 02451.

{ddagger} Present address: Nabriva Therapeutics AG, 1112 Vienna, Austria.

Antimicrobial Agents and Chemotherapy, September 2009, p. 3777-3781, Vol. 53, No. 9
0066-4804/09/$08.00+0     doi:10.1128/AAC.00026-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»